Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 6
1982 5
1983 2
1984 4
1985 5
1986 10
1987 8
1988 12
1989 11
1990 13
1991 11
1992 16
1993 11
1994 7
1995 16
1996 11
1997 15
1998 14
1999 15
2000 14
2001 26
2002 26
2003 55
2004 52
2005 71
2006 55
2007 73
2008 89
2009 93
2010 79
2011 120
2012 135
2013 158
2014 203
2015 189
2016 202
2017 229
2018 236
2019 278
2020 338
2021 447
2022 483
2023 540
2024 437
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,324 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice.
Duan J, Wang Z, Duan R, Yang C, Zhao R, Feng Q, Qin Y, Jiang J, Gu S, Lv K, Zhang L, He B, Birnbaumer L, Yang S, Chen Z, Yang Y. Duan J, et al. Among authors: gu s. Hepatology. 2022 Jan;75(1):140-153. doi: 10.1002/hep.32148. Epub 2021 Nov 27. Hepatology. 2022. PMID: 34510514 Free PMC article.
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade.
Gu SS, Zhang W, Wang X, Jiang P, Traugh N, Li Z, Meyer C, Stewig B, Xie Y, Bu X, Manos MP, Font-Tello A, Gjini E, Lako A, Lim K, Conway J, Tewari AK, Zeng Z, Sahu AD, Tokheim C, Weirather JL, Fu J, Zhang Y, Kroger B, Liang JH, Cejas P, Freeman GJ, Rodig S, Long HW, Gewurz BE, Hodi FS, Brown M, Liu XS. Gu SS, et al. Cancer Discov. 2021 Jun;11(6):1524-1541. doi: 10.1158/2159-8290.CD-20-0812. Epub 2021 Feb 15. Cancer Discov. 2021. PMID: 33589424 Free PMC article.
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, Boehnke K, Lynch KN, Xu R, Zarrella DT, Gu S, Cejas P, Lim K, Long HW, Elias KM, Horowitz NS, Feltmate CM, Muto MG, Worley MJ Jr, Berkowitz RS, Matulonis UA, Nucci MR, Crum CP, Rueda BR, Brown M, Liu XS, Hill SJ. Wan C, et al. Among authors: gu s. Cancer Res. 2021 Jan 1;81(1):158-173. doi: 10.1158/0008-5472.CAN-20-1674. Epub 2020 Nov 6. Cancer Res. 2021. PMID: 33158814 Free PMC article.
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, Ying J, Lu Y, Meng Z, Pan H, Yang P, Zhang H, Chen X, Xu A, Cui C, Zhu B, Wu J, Xin X, Wang J, Shan J, Chen J, Zheng Z, Xu L, Wen X, You Z, Ren Z, Liu X, Qiu M, Wu L, Chen F. Qin S, et al. Among authors: gu s. J Clin Oncol. 2021 Sep 20;39(27):3002-3011. doi: 10.1200/JCO.21.00163. Epub 2021 Jun 29. J Clin Oncol. 2021. PMID: 34185551 Free PMC article. Clinical Trial.
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.
Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, Liu J, Ren Z, Xiong J, Mao X, Zhang L, Yang J, Li L, Chen X, Wang Z, Gu K, Chen X, Pan Z, Ma K, Zhou X, Yu Z, Li E, Yin G, Zhang X, Wang S, Wang Q. Xu J, et al. Among authors: gu s. Clin Cancer Res. 2021 Feb 15;27(4):1003-1011. doi: 10.1158/1078-0432.CCR-20-2571. Epub 2020 Oct 21. Clin Cancer Res. 2021. PMID: 33087333 Clinical Trial.
4,324 results